Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase

Prasad et al. 10.1073/pnas.0501432102.

Supporting Information

Files in this Data Supplement:

Supporting Table 1
Supporting Table 2
Supporting Figure 6
Supporting Figure 7
Supporting Table 3
Supporting Figure 8




Fig. 6. Saturation kinetic analysis of 5-hydroxytryptamine (5-HT) transport by human serotonin transporter (hSERT), Pro339Leu (P339L), and Ile425Val (I425V). Plots are derived from mean activities obtained in three or more separate experiments. Kinetic values obtained were the following: hSERT, Vmax, 416.2 ± 19 fmol per well per min: Km, 1.00 ± 0.17 mM; Pro339Leu, Vmax, 1.2 ± 0.11 fmol per well per min: Km, ND; Ile425Val, Vmax, 789.5 ± 28 fmol per well per min; Km, 0.56 ± 0.13 mM.





Fig. 7. Impact of SERT-coding variants on total and cell surface [125I]RTI-55 (3b-(4-iodophenyl)tropan-2b-carboxylic acid methyl ester) binding. HeLa cells transiently transfected with hSERT or one of the SERT-coding variants were subjected to intact cell-binding assays at 4°C with the cocaine analog [125I]RTI-55(5 nM) as described in Materials and Methods. (A) Total binding values as defined with paroxetine (10 mM) as displacer. (B) Surface labeling by [125I]RTI-55 as defined with 5-HT (100 mM) as displacer. In vehicle-treated cells, hSERT total binding (fmol per 106 cells) was 618.2 ± 27.9, and the surface binding was 173.8 ± 6.6. Results for A and B reflect mean values ± SEM of three separate experiments normalized to hSERT (100%). Binding levels were analyzed by means of a one-way ANOVA followed by post hoc Dunnett’s tests comparing mutant means with hSERT (*, P < 0.05 taken as significant).





Fig. 8. Modulation of hSERT and coding variants by phorbol ester. Transfected cells treated with 10 or 100 m M b-phorbol 12-myristate 13-acetate (b-PMA) for 15 min in the presence or absence of the PKC antagonist bisindolylmaleimide (BIM) were assayed for 5-HT transport as described in Materials and Methods. P339L was not tested due to low basal transport activity. Results represent mean values ± SEM of three separate experiments normalized to each mutant’s vehicle-treated control (100%). Data were analyzed using a two-way ANOVA followed by a post hoc Bonferonni test to evaluate differences in PMA effects comparing hSERT with each coding variant (*, P < 0.05 taken as significant). Stauro, staurosporine; BIM-I, bisindolylmaleimide I.





Table 1. Human SERT nonsynonymous variants

Nucleotide change in NCBI sequence deposit

Nucleotide change in protein sequence

Location in SERT protein

Position in exon

Allele frequency

Amino acid change

A483G

A10G

NH2-terminal

Exon 2

1/900 (3)

Thr4Ala (3)

G640C

G167C

NH2-terminal

Exon 2

5/114 (2)

4/900 (3)

Gly56Ala (2, 3)

G1074A

G643A

ECL2

Exon 4

1/900 (3)

Glu215Lys (3)

C1999A

C763A

TM4

Exon 5

1/200(Dep) (1)

Leu255Met (1)

C262T

C878T

TM5

Exon 6

1/900 (3)

Ser293Phe (3)

C767T

C1016T

TM6

Exon 7

1/900 (3)

Pro339Leu (3)

C258A

C1084A

TM7

Exon 8

1/900 (3)

Leu362Met (3)

A318G

A1273G

TM8

Exon 9

1/900 (3), 2/60(OCD) (4)

Ile425Val (3, 4)

A469C

A1815C

COOH-terminal

Exon 13

1/114 (2);

1/900 (3)

Lys605Asn (2, 3)

C274T

C1861T

COOH-terminal

Exon 14

1/900 (3)

Pro621Ser (3)

NCBI, National Center for Biotechnology Information; ECL, extracellular loop; TM, transmembrane domain; Dep, depression; OCD, obsessive-compulsive disorder.

1. Di Bella, D., Catalano, M., Balling, U., Smeraldi, E. & Lesch, K. P. (1996) Am. J. Med. Genet. 67, 541-545.

2. Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Lane, C. R., Lim, E. P., Kalayanaraman, N., Nemesh, J., et al. (1999) Nat. Genet. 22, 231-238.

3. Glatt, C. E., DeYoung, J. A., Delgado, S., Service, S. K., Giacomini, K. M., Edwards, R. H., Risch, N. & Freimer, N. B. (2001) Nat. Genet. 27, 435-438.

4. Ozaki, N., Goldman, D., Kaye, W. H., Plotnicov, K., Greenberg, B. D., Lappalainen, J., Rudnick, G. & Murphy, D. L. (2003) Mol. Psychiatry 8, 895, 933-936.





Table 2. Sequence conservation at sites of human SERT-coding variants

 

Thr4

Gly56

Glu215

Leu255

Ser293

Pro339

Leu362

Ile425

Lys605

Pro621

hSERT

T

G

E

L

S

P

L

I

K

P

rSERT

T

G

Q

L

S

P

L

I

K

P

mSERT

T

G

Q

L

S

P

L

I

K

P

gpSERT

T

G

E

L

S

P

L

I

K

P

bovSERT

T

G

E

L

L

P

L

I

K

P

dSERT

S

T

E

L

I

P

L

I

R

V

ceSERT

W

H

D

M

S

P

V

F

Y

S

hNET

A

L

L

L

F

A

L

V

W

I

hDAT

S

T

G

L

T

V

I

V

R

V

hGAT1

S

T

T

V

R

V

A

L

Y

I

hSERT, human SERT; rSERT, rat ; mSERT, mouse; gpSERT, guinea pig; bovSERT, bovine; dSERT, Drosophila melanogaster; ceSERT, Caenorhabditis elegans; hNET, human norepinephrine transporter; hDAT, human dopamine transporter; hGAT1, human GABA transporter type 1.





Table 3. Pharmacological sensitivities of human SERT-coding variants

hSERT variant

Citalopram

Fluoxetine

Cocaine

hSERT

3.8 ± 1.4

21 ± 7

345 ± 57

T4A

4.7 ± 1.9

46 ± 16

468 ± 22

G56A

8.9 ± 2.8

61 ± 24

2158 ± 394*

E215K

5.2 ± 2.7

28 ± 13

543 ± 149

L255M

12.3 ± 1.2*

68 ± 6

1852 ± 41*

S293F

11.1 ± 4.5

40 ± 15

1603 ± 398*

P339L

13.4 ± 5.3*

132 ± 72*

3787 ± 981*

L362M

6.9 ± 3.1

46 ± 13

1700 ± 665*

I425V

16.5 ± 6.4*

23 ± 10

1188 ± 383

K605N

5.7 ± 2.2

37 ± 15

1567 ± 480*

P621S

3.6 ± 1.7

29 ± 5

802 ± 232

Ki values (nM ± SEM) were determined from three or more separate SERT uptake inhibition assays. *, P < 0.05, one-way ANOVA with a post hoc Dunnett’s test comparing variant with hSERT for the same compound.

This Article

  1. PNAS August 9, 2005 vol. 102 no. 32 11545-11550
  1. AbstractFree
  2. Figures Only
  3. Full Text
  4. Full Text (PDF)
  5. » Supporting Information